EA202090699A3 - Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения - Google Patents

Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения

Info

Publication number
EA202090699A3
EA202090699A3 EA202090699A EA202090699A EA202090699A3 EA 202090699 A3 EA202090699 A3 EA 202090699A3 EA 202090699 A EA202090699 A EA 202090699A EA 202090699 A EA202090699 A EA 202090699A EA 202090699 A3 EA202090699 A3 EA 202090699A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions containing
buffer
vaccines
application
contain
Prior art date
Application number
EA202090699A
Other languages
English (en)
Russian (ru)
Other versions
EA202090699A2 (ru
Inventor
Чарльз Ричардсон
Роберт Ф. Баргаце
Пол М. Мендельман
Original Assignee
Такеда Вэксинс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090699(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Вэксинс, Инк. filed Critical Такеда Вэксинс, Инк.
Publication of EA202090699A2 publication Critical patent/EA202090699A2/ru
Publication of EA202090699A3 publication Critical patent/EA202090699A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EA202090699A 2011-07-11 2012-07-11 Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения EA202090699A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (2)

Publication Number Publication Date
EA202090699A2 EA202090699A2 (ru) 2020-07-31
EA202090699A3 true EA202090699A3 (ru) 2020-11-30

Family

ID=47506489

Family Applications (3)

Application Number Title Priority Date Filing Date
EA202090699A EA202090699A3 (ru) 2011-07-11 2012-07-11 Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
EA201490258A EA029470B1 (ru) 2011-07-11 2012-07-11 Способ стимулирования формирования защитного иммунитета против норовируса
EA201792407A EA035442B1 (ru) 2011-07-11 2012-07-11 Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201490258A EA029470B1 (ru) 2011-07-11 2012-07-11 Способ стимулирования формирования защитного иммунитета против норовируса
EA201792407A EA035442B1 (ru) 2011-07-11 2012-07-11 Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения

Country Status (29)

Country Link
US (5) US9801934B2 (enExample)
EP (3) EP2731621B1 (enExample)
JP (2) JP6208659B2 (enExample)
KR (1) KR102096937B1 (enExample)
CN (3) CN105031637A (enExample)
AU (2) AU2012282658B2 (enExample)
BR (1) BR112014000656A2 (enExample)
CA (1) CA2841356C (enExample)
CL (1) CL2014000082A1 (enExample)
CR (2) CR20190540A (enExample)
DK (1) DK3299030T3 (enExample)
DO (2) DOP2014000004A (enExample)
EA (3) EA202090699A3 (enExample)
EC (1) ECSP14013201A (enExample)
ES (2) ES2926487T3 (enExample)
GE (1) GEP201706668B (enExample)
HK (2) HK1199202A1 (enExample)
IL (1) IL230356B (enExample)
MA (1) MA35414B1 (enExample)
MX (2) MX356586B (enExample)
MY (1) MY170746A (enExample)
PE (1) PE20140845A1 (enExample)
PH (3) PH12014500093A1 (enExample)
PL (2) PL2731621T3 (enExample)
SG (1) SG10201605644WA (enExample)
TN (1) TN2014000008A1 (enExample)
UA (1) UA117732C2 (enExample)
WO (1) WO2013009849A1 (enExample)
ZA (2) ZA201401012B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
CA2926225A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
US11306292B2 (en) * 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2019158653A1 (en) * 2018-02-15 2019-08-22 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
CN117098846A (zh) 2021-03-29 2023-11-21 电化株式会社 诺如病毒来源的肽、多核苷酸、抗体、组合物、鉴定诺如病毒的中和表位的方法
JP2024519800A (ja) 2021-05-21 2024-05-21 タケダ ワクチン，インコーポレイテッド 固体組成物、フリーズドライ方法およびガラスバイアル
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
EP0635056A1 (en) 1992-04-08 1995-01-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Wild-type measles virus glycoproteins: vaccine and detection method therefor
AU4851493A (en) 1992-09-07 1994-03-29 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
RO117541B1 (ro) 1994-05-16 2002-04-30 Merck & Co Inc Procedeu pentru prepararea unui vaccin de papillomavirus uman, pentru administrare la om
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
DK0973546T3 (da) 1997-04-08 2004-06-28 Merck & Co Inc Stabiliserede formuleringer med human papillomavirus
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
ES2262333T3 (es) 1998-08-14 2006-11-16 MERCK & CO., INC. Procedimiento para purificar particulas similares a virus de papilomavirus humano.
ATE323508T1 (de) 1998-12-17 2006-05-15 Merck & Co Inc Synthetische virus-ähnliche partikel mit heterologen epitopen.
EP1150712B1 (en) * 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
ES2398413T3 (es) 1999-06-22 2013-03-19 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Kit de detección de SRSV
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2003217413A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
AU2003242742B2 (en) 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US20040213745A1 (en) 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EP1809325B1 (en) 2004-10-20 2013-11-20 Sanofi Pasteur Biologics, LLC Vaccines against japanese encephalitis virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2593176A1 (en) 2005-01-05 2006-07-13 Peter D. Katsikis Delivery vehicles, bioactive substances and viral vaccines
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
ES2424229T3 (es) 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
KR20080018176A (ko) 2005-06-01 2008-02-27 다우 글로벌 테크놀로지스 인크. 다가 바이러스 유사 입자 생산 방법
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP1969001A2 (en) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
SG10201701988TA (en) * 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
AU2008299589B2 (en) 2007-09-12 2014-06-26 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
CN101918028B (zh) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
DK2324113T3 (en) 2008-08-08 2018-04-16 Takeda Vaccines Inc VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY
AU2009338516A1 (en) * 2009-01-22 2011-08-18 Pharmathene, Inc. Stable vaccine compositions and methods of use
AU2010212547B2 (en) * 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
US8980275B2 (en) 2010-01-21 2015-03-17 Takeda Vaccines, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
CN106177940A (zh) * 2010-05-26 2016-12-07 西莱克塔生物科技公司 含有佐剂的合成纳米载体的剂量选择
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN112972492B (zh) 2015-12-16 2024-11-08 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
PH12021552003A1 (en) 2019-02-15 2022-12-05 Editas Medicine Inc Modified natural killer (nk) cells for immunotherapy

Also Published As

Publication number Publication date
ECSP14013201A (es) 2014-05-31
UA117732C2 (uk) 2018-09-25
DOP2022000030A (es) 2022-06-30
EP2731621B1 (en) 2017-11-01
CN103874507A (zh) 2014-06-18
US20180185468A1 (en) 2018-07-05
US20230338503A1 (en) 2023-10-26
CA2841356A1 (en) 2013-01-17
JP6208659B2 (ja) 2017-10-04
US20160000899A1 (en) 2016-01-07
PH12018501515A1 (en) 2019-02-04
EA202090699A2 (ru) 2020-07-31
ZA201401012B (en) 2015-05-27
MX356586B (es) 2018-06-05
EA201792407A2 (ru) 2018-03-30
ES2656527T3 (es) 2018-02-27
HK1198136A1 (en) 2015-03-13
ES2926487T3 (es) 2022-10-26
US10675341B2 (en) 2020-06-09
PH12014500093A1 (en) 2014-03-17
HK1215154A1 (zh) 2016-08-19
AU2012282658A1 (en) 2013-03-14
WO2013009849A1 (en) 2013-01-17
EP3299030A1 (en) 2018-03-28
AU2012282658B2 (en) 2014-11-27
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
CR20190540A (es) 2022-04-04
US11701420B2 (en) 2023-07-18
MA35414B1 (fr) 2014-09-01
MY170746A (en) 2019-08-27
PH12021551773A1 (en) 2022-08-01
EA201792407A3 (ru) 2018-07-31
EP3299030B1 (en) 2022-06-08
US20210085778A1 (en) 2021-03-25
PL2731621T3 (pl) 2018-10-31
PE20140845A1 (es) 2014-08-03
EP2731621A1 (en) 2014-05-21
ZA201500915B (en) 2016-06-29
KR102096937B1 (ko) 2020-04-03
EA029470B1 (ru) 2018-03-30
CN105031637A (zh) 2015-11-11
PH12018501515B1 (en) 2022-02-18
JP6613259B2 (ja) 2019-11-27
AU2015200836B2 (en) 2016-08-25
NZ620865A (en) 2015-08-28
JP2017214357A (ja) 2017-12-07
IL230356B (en) 2019-05-30
JP2014520852A (ja) 2014-08-25
CR20140069A (es) 2014-06-27
AU2015200836A1 (en) 2015-03-12
US9867876B2 (en) 2018-01-16
CL2014000082A1 (es) 2014-07-04
EA201490258A1 (ru) 2014-05-30
CA2841356C (en) 2022-03-01
DOP2014000004A (es) 2014-10-31
BR112014000656A2 (pt) 2017-02-14
TN2014000008A1 (en) 2015-07-01
SG10201605644WA (en) 2016-09-29
EP2731621A4 (en) 2015-03-25
MX2014000411A (es) 2014-08-26
HK1199202A1 (en) 2015-06-26
MX379496B (es) 2025-03-11
EP4112074A1 (en) 2023-01-04
KR20140066160A (ko) 2014-05-30
EA035442B1 (ru) 2020-06-17
GEP201706668B (en) 2017-05-25
CN108567975A (zh) 2018-09-25
NZ710919A (en) 2017-12-22
DK3299030T3 (da) 2022-09-05
PL3299030T3 (pl) 2022-12-05

Similar Documents

Publication Publication Date Title
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
MX2018007627A (es) Vacuna contra el virus del zika.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
MY197723A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
EA201590491A1 (ru) Иммуногенная композиция
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX2015010102A (es) Vacuna de subunidades anti-mycoplasma spp.
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
IN2014DN09445A (enExample)
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
UA106111C2 (uk) Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію